New hope for rare kidney cancer: drug duo targets tough tumors
NCT ID NCT05831891
First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study tests two drugs, fruquintinib and serplulimab, as a first treatment for people with a rare and hard-to-treat kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will take part, and researchers will also look for markers that predict who benefits most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CLEAR RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renji Hospital
Shanghai, Shanghai Municipality, 200123, China
Conditions
Explore the condition pages connected to this study.